Late-onset motoneuron disease caused by a functionally modified AMPA receptor subunit.
about
Inhibitory synaptic regulation of motoneurons: a new target of disease mechanisms in amyotrophic lateral sclerosis.Adaptive gene regulation in the Striatum of RGS9-deficient miceTranscript diversification in the nervous system: a to I RNA editing in CNS function and disease developmentAmygdala size in amyotrophic lateral sclerosis without dementia: an in vivo study using MRI volumetryGlutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis.BMAA--an unusual cyanobacterial neurotoxin.A-to-I RNA editing and human disease.Unravelling the enigma of selective vulnerability in neurodegeneration: motor neurons resistant to degeneration in ALS show distinct gene expression characteristics and decreased susceptibility to excitotoxicity.Exposure of neurons to excitotoxic levels of glutamate induces cleavage of the RNA editing enzyme, adenosine deaminase acting on RNA 2, and loss of GLUR2 editing.The essential role of AMPA receptor GluR2 subunit RNA editing in the normal and diseased brainAstrocytes regulate GluR2 expression in motor neurons and their vulnerability to excitotoxicity.Novel toxicity of the unedited GluR2 AMPA receptor subunit dependent on surface trafficking and increased Ca2+-permeability.AMPA Receptor Phosphorylation and Synaptic Colocalization on Motor Neurons Drive Maladaptive Plasticity below Complete Spinal Cord Injury.TNF-α triggers rapid membrane insertion of Ca(2+) permeable AMPA receptors into adult motor neurons and enhances their susceptibility to slow excitotoxic injury.Dynamic regulation of RNA editing of ion channels and receptors in the mammalian nervous system.TARP γ-7 selectively enhances synaptic expression of calcium-permeable AMPARs.Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity.Evidence-based drug treatment in amyotrophic lateral sclerosis and upcoming clinical trials.ADARs: allies or enemies? The importance of A-to-I RNA editing in human disease: from cancer to HIV-1.Ca permeable AMPA channels in diseases of the nervous system.Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS/FTD diseases.Glutamate receptors localize postsynaptically at neuromuscular junctions in mice.Selective vulnerability of motoneuron and perturbed mitochondrial calcium homeostasis in amyotrophic lateral sclerosis: implications for motoneurons specific calcium dysregulation.Intrathecal infusion of a Ca(2+)-permeable AMPA channel blocker slows loss of both motor neurons and of the astrocyte glutamate transporter, GLT-1 in a mutant SOD1 rat model of ALS.Abnormal exocytotic release of glutamate in a mouse model of amyotrophic lateral sclerosis.GluR2 deficiency accelerates motor neuron degeneration in a mouse model of amyotrophic lateral sclerosis.C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca2+-permeable AMPA receptor-mediated excitotoxicity.EAAT2 and the Molecular Signature of Amyotrophic Lateral Sclerosis.Ionic Homeostasis Maintenance in ALS: Focus on New Therapeutic Targets
P2860
Q27687333-71E4DAF6-27F7-4F5B-A18D-9DA4E263D043Q28541409-F2E8271D-2FE1-4736-B3B6-4F0FEDD98993Q30465782-7E9267D3-A90D-4FD0-9DB0-83CCF1CE3F64Q33267637-8891FC32-1AB3-4C4C-B5B4-C9349D052042Q33742729-23C06D04-F0D3-4233-8E9E-4D5ECA71CBFDQ34020249-F4712765-872D-4B78-9C01-C62403382EE3Q34162058-E29A5126-D90A-4565-9808-132234A59E4BQ34473390-CE0D6721-17F4-4669-87AD-DF507EECDEEEQ35147567-DDA0DF8A-CB8A-4872-ACCE-B460CD2ED636Q35882740-762CA321-3AA4-48FD-90C6-1F76852AFA34Q35990227-0BA3E92B-4C96-47C0-9EC2-6CBC0A948A2BQ36074474-F02D9649-2AA5-42D6-85ED-BE40EC0B70DAQ36368097-E9737579-193E-490A-8173-8E6EC587FA92Q36400417-48AE3D18-6094-4301-B23B-2EDDDF2DF6B3Q37222025-5E87D582-510A-4654-8695-A03F68E0DD62Q37381920-EE418201-D585-4EFB-8E64-F5FAE8B5A5FCQ37709583-6D423309-E883-453B-9EB4-21FF220A1482Q37823334-47076829-79D7-4467-B294-73FC918487CBQ37891173-1BA691F1-E195-4265-9BDE-6D0671B251CEQ37958853-F7799063-258D-44E7-A1C7-1065882D6532Q38210259-C00B7D91-9196-4DD4-83FD-4C2761E92607Q38363251-35F1822B-CB25-4BE9-BBEF-CCA0F3FB8C10Q38521756-D82C4BC4-B549-4528-B76C-8E01DB100472Q40296129-7A7497EE-20DD-4F95-AC41-58A3DEC0EDA1Q42481571-EFBDB248-99F3-4DBE-952E-77D41EC98B36Q46617278-254A9473-502B-4AE6-9169-ABCEB421ED3CQ47841147-37939CC9-D105-44CC-9A81-69E000A8939DQ51824569-BE30DDFE-A273-4363-925B-756798451221Q57170405-6944AE98-4CD6-4DFB-B29A-FB0F6E2CF9E8
P2860
Late-onset motoneuron disease caused by a functionally modified AMPA receptor subunit.
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Late-onset motoneuron disease caused by a functionally modified AMPA receptor subunit.
@ast
Late-onset motoneuron disease caused by a functionally modified AMPA receptor subunit.
@en
type
label
Late-onset motoneuron disease caused by a functionally modified AMPA receptor subunit.
@ast
Late-onset motoneuron disease caused by a functionally modified AMPA receptor subunit.
@en
prefLabel
Late-onset motoneuron disease caused by a functionally modified AMPA receptor subunit.
@ast
Late-onset motoneuron disease caused by a functionally modified AMPA receptor subunit.
@en
P2093
P2860
P356
P1476
Late-onset motoneuron disease caused by a functionally modified AMPA receptor subunit.
@en
P2093
Anthony J Groom
Bettina Hartmann
Chrysanthy Ikonomidou
Gerald Müller
Hans-Christian Kornau
Iris Bresink
Karsten Tschauner
Lechoslaw Turski
Rohini Kuner
Stefan Waibel
P2860
P304
P356
10.1073/PNAS.0501316102
P407
P577
2005-04-12T00:00:00Z